Medical Equipment/Supplies/Accessories · Founded 1995 · www.bostoncommerce.net · BSE 531458 · · ISIN INE109B01019
No Notes Added Yet
Business
Boston Commerce Ltd. (BOSTON) is an Indian company operating in the Medical Equipment/Supplies/Accessories sector. The company likely focuses on the manufacturing, distribution, and/or trading of a range of medical devices, consumables, diagnostic equipment, or surgical instruments. Its core business model would involve supplying these products to various healthcare providers, including hospitals, clinics, diagnostic centers, government health programs, and potentially directly to consumers or pharmacies for home care equipment. Revenue is primarily generated through the sale of its medical products and possibly through related services such as installation, maintenance, and after-sales support.
Revenue Mix
Without specific financial data, the exact key segments and their revenue contribution for Boston Commerce Ltd. are unknown. However, companies in this industry typically segment their business by:
Product Categories: Such as diagnostic imaging equipment, surgical instruments, orthopedic implants, patient monitoring systems, medical consumables (e.g., gloves, syringes, catheters), or laboratory equipment.
Therapeutic Areas: Focusing on specific medical specialties like cardiology, oncology, orthopedics, or critical care.
Customer Types: Distinguishing between sales to private hospitals, government institutions, individual practitioners, or exports.
The specific mix would depend on Boston Commerce Ltd.'s product portfolio and market strategy.
Industry
The Indian Medical Equipment/Supplies/Accessories industry is characterized by significant growth potential, driven by rising healthcare expenditure, increasing disease burden, and government initiatives to improve healthcare access. The market is competitive, featuring a mix of large multinational corporations, established domestic manufacturers, and smaller regional players. Positioning for Boston Commerce Ltd. would depend on its specific product offerings (e.g., niche vs. broad portfolio), distribution network, technological capabilities, and pricing strategy. Without further information, it is difficult to ascertain its precise standing relative to peers, but it operates within a dynamic and increasingly regulated landscape.
MOAT
Given the lack of specific company details, it's not possible to definitively state whether Boston Commerce Ltd. possesses a durable competitive advantage. However, potential sources of competitive advantage in this sector could include:
Strong Distribution Network: An extensive and efficient reach across India to hospitals and healthcare providers.
Specialized Product Portfolio: Developing proprietary or highly specialized medical devices with strong intellectual property protection.
Regulatory Approvals & Compliance: A proven track record of navigating complex regulatory pathways (e.g., CDSCO approvals) for a broad range of products, which can be a barrier to entry.
Cost Leadership: Ability to manufacture or procure products at a significantly lower cost while maintaining quality.
Brand Reputation & Relationships: Established trust with healthcare professionals and long-standing relationships with key customers.
Growth Drivers
Key factors that could drive growth for Boston Commerce Ltd. over the next 3-5 years include:
Growing Indian Healthcare Market: Increasing per capita healthcare spending, expansion of health insurance coverage, and government initiatives like Ayushman Bharat.
Aging Population & Chronic Diseases: Rising prevalence of chronic and lifestyle diseases requiring ongoing medical intervention and equipment.
Healthcare Infrastructure Development: Expansion of hospitals, clinics, and diagnostic centers, particularly in Tier 2 and Tier 3 cities.
"Make in India" Initiatives: Government push for domestic manufacturing of medical devices, potentially offering incentives or preferential procurement.
Technological Advancements: Introduction of innovative and advanced medical technologies, driving demand for new equipment.
Medical Tourism: India's growing prominence as a medical tourism destination increases demand for high-quality medical equipment.
Risks
Boston Commerce Ltd. faces several risks common to the medical equipment industry:
Intense Competition: From both large global players and domestic manufacturers, leading to pricing pressure and market share battles.
Regulatory Changes: Strict and evolving regulatory landscape in India (e.g., CDSCO norms, price controls on essential medical devices) can impact product approvals, costs, and market access.
Technological Obsolescence: Rapid advancements in medical technology can render existing products outdated, requiring continuous R&D investment.
Supply Chain Disruptions: Reliance on global supply chains for raw materials or components can lead to delays and increased costs.
Foreign Exchange Fluctuations: If the company relies on importing components or finished products, currency volatility can impact profitability.
Product Recalls & Litigation: Risks associated with product quality, safety, and potential recalls or legal disputes.
Healthcare Spending & Policy Changes: Sensitivity to government healthcare spending priorities and insurance reimbursement policies.
Management & Ownership
As an Indian company, Boston Commerce Ltd. is likely promoter-driven, but without specific information, details about the promoters, their experience, or the management team's quality are unknown. The effectiveness of management would depend on their ability to navigate the complex regulatory environment, drive innovation, manage competition, and build strong distribution channels. Ownership structure details (e.g., promoter holding, institutional holding, public float) are also unavailable, though as a publicly traded company (indicated by ticker BOSTON), it would have a public shareholding component.
Outlook
Boston Commerce Ltd. operates in a sector with significant inherent tailwinds driven by India's expanding healthcare needs and infrastructure. The demand for medical equipment and supplies is expected to grow steadily, offering a favorable market environment.
However, the company will need to effectively navigate a highly competitive landscape, evolving regulatory requirements, and the constant need for technological innovation. Its success will hinge on its ability to build a robust product portfolio, establish efficient distribution, maintain stringent quality standards, and strategically adapt to market dynamics. While the broader industry outlook is positive, Boston Commerce Ltd.'s specific performance will depend on its execution, competitive differentiation, and operational efficiency within this complex environment.
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 7 |
| Operating Profit | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -7 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Tax | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -7 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 |
| Profit After Adjustments | 0 | -0 | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -7 |
| Adjusted Earnings Per Share | 0 | -0.2 | 0 | -0 | -0.1 | -0.7 | 0.1 | 0.1 | -0 | -10.3 |
| #(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenditure | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 7 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -1 | -7 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -1 | -7 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -1 | -7 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -1 | -7 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0.2 | -0.8 | -10.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 28% | NA% | NA% | -5% |
| ROE Average | -9% | -4% | -2% | -1% |
| ROCE Average | -6% | -3% | -2% | -1% |
| #(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | 6 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Other Non-Current Liabilities | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Total Current Liabilities | 0 | 0 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 |
| Total Liabilities | 7 | 7 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | 15 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Total Current Assets | 0 | 1 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 9 |
| Total Assets | 7 | 7 | 9 | 9 | 10 | 11 | 11 | 11 | 11 | 11 | 15 |
| #(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 1 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -5 |
| Cash Flow from Investing Activities | -0 | -1 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Net Cash Inflow / Outflow | -0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0.2 | -0.78 |
| CEPS(Rs) | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | -0.2 | -0.78 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 9.42 | 9.42 | 9.42 | 9.42 | 9.43 | 9.42 | 9.42 | 9.42 | 9.41 | 9.21 | 8.43 |
| Core EBITDA Margin(%) | -3.37 | 2.25 | 0.09 | 0.29 | 0.07 | 0 | 0 | 0 | 0 | 0 | -284.31 |
| EBIT Margin(%) | 1.78 | 1.18 | 0.04 | 0.18 | 0.07 | 0 | 0 | 0 | 0 | 0 | -284.31 |
| Pre Tax Margin(%) | 0.83 | 0.2 | 0.03 | 0.15 | 0.05 | 0 | 0 | 0 | 0 | 0 | -284.31 |
| PAT Margin (%) | 0.57 | 0.11 | 0.02 | 0.1 | 0.05 | 0 | 0 | 0 | 0 | 0 | -284.31 |
| Cash Profit Margin (%) | 0.57 | 1.18 | 0.06 | 0.22 | 0.05 | 0 | 0 | 0 | 0 | 0 | -284.31 |
| ROA(%) | 0 | 0 | 0 | 0.01 | 0 | -0.01 | -0.02 | -0.02 | -0.02 | -1.33 | -4.3 |
| ROE(%) | 0 | 0 | 0 | 0.01 | 0.01 | -0.02 | -0.03 | -0.03 | -0.03 | -2.16 | -8.86 |
| ROCE(%) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | -0.02 | -0.03 | -0.03 | -0.03 | -1.9 | -5.86 |
| Receivable days | 0 | 0 | 364.39 | 1179.99 | 1165.54 | 0 | 0 | 0 | 0 | 0 | 5457.75 |
| Inventory Days | 0 | 0 | 0 | 0 | 8.36 | 0 | 0 | 0 | 0 | 0 | 274.56 |
| Payable days | 0 | 0 | 182.5 | 1263.08 | 1321.08 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 9750 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0.41 | 1.59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.92 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 58.6 | 183.44 | 5.24 | 14.73 | 11.16 | 0 | 0 | 0 | 0 | 0 | 86.94 |
| EV/Core EBITDA(x) | 3290.37 | 8135.36 | 6132.93 | 5055.23 | 0 | -5352.55 | -4006.94 | -4156.6 | -3552.59 | -55.55 | -30.58 |
| Net Sales Growth(%) | -66.92 | 18.22 | 2509.43 | -64.36 | 31.19 | -100 | 0 | 0 | 0 | 0 | 0 |
| EBIT Growth(%) | 110.16 | -21.71 | -2.32 | 41.97 | -44.13 | -378.6 | -33.6 | 3.59 | -17.02 | -6295.45 | -288.98 |
| PAT Growth(%) | 103.28 | -78.38 | 301.99 | 120.79 | -34.94 | -532.71 | -29.65 | 3.59 | -17.02 | -6295.45 | -288.98 |
| EPS Growth(%) | 103.3 | -75 | 200 | 154.35 | -34.94 | -523.03 | -33.33 | 3.57 | -14.81 | -6380.65 | -289.05 |
| Debt/Equity(x) | 0.02 | 0.02 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.92 |
| Current Ratio(x) | 0.04 | 8.29 | 1.44 | 1.37 | 1.28 | 1.24 | 1.24 | 1.24 | 1.24 | 1.19 | 2.07 |
| Quick Ratio(x) | 0.04 | 8.29 | 1.44 | 1.37 | 1.27 | 1.2 | 1.2 | 1.2 | 1.2 | 1.16 | 2.03 |
| Interest Cover(x) | 1.87 | 1.21 | 2.54 | 5.7 | 3.18 | -32.8 | 0 | 0 | 0 | 0 | 0 |
| Total Debt/Mcap(x) | 0.04 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.48 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7 | 1.7 |
| Public | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 96.15 | 96.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Public | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.68 | 0.69 | 0.67 | 0.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | — | — | — | — |
| Operating Profit CAGR | — | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | +28% | — | — | -5% |
| ROE Average | -9% | -4% | -2% | -1% |
| ROCE Average | -6% | -3% | -2% | -1% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.7 | 1.7 |
| Public | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 97.86 | 96.15 | 96.15 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 |
| Public | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | 0.68 | 0.69 | 0.67 | 0.67 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.